ACE and heart failure: In the PARADIGM-HF study (Prospective Comparison of ARNI [Angiotensin Receptor Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure),17 sacubitril-valsartan demonstrated 1.3- and 0.9-point improvements in KCCQ-OSS and KCCQ-CSS, respectively, over enalapril after 8 months of treatment (although true baseline measurement of KCCQ was not done, which complicates the interpretation of these data).